Pipeline And Milestones

Breaking Boundaries Engineering The Future of Targeted Medicines
Platform Candidate Program Area
Pre-Clinical
Phase 1
Phase 2
Phase 3
Status Partner Next Milestone
Gene-Based Therapy
Ofra-Vec (ofranergene obadenovec: 'VB-111') Platinum Resistant Ovarian Cancer (PROC)
Phase 3
Registration Enabling Study (OVAL)
Status: Fully Enrolled
GOG Foundation
Fully Enrolled Nano-Carrier (Japan) Wholly-owned ROW PFS Readout (Primary Endpoint) - 3Q22 OS Readout (Primary Endpoint) - 2023
Recurrent Glioblastoma
Phase 2
Randomized Controlled Study
Status: Recruiting
UCLA Memorial Sloan Kettering Cancer Center Dana Farber Cancer Institute UT Health San Antonio
Recruiting Preliminary Data - 2022
Colorectal Cancer
Phase 2
Nivolumab Combo
Status: Recruiting
National Cancer Institute
Recruiting Preliminary Data - 2022
VB-601 Anti-inflammatory
Phase 1
Status: IND Enabling Studies
IND Enabling Studies Wholly-owned First in Human - 2H22